Prof. Dr. Iqbal Munir
Chief of Endocrinology and Metabolism,
Chair, Institutional Review Board,
Riverside University Health System Medical Center
Clinical Professor, UCR School of Medicine, USA
Prof. Dr. Iqbal Munir
Chief of Endocrinology and Metabolism,
Chair, Institutional Review Board,
Riverside University Health System Medical Center
Clinical Professor, UCR School of Medicine, USA
Abstract
Type 2 diabetes mellitus poses a substantial global public health concern, contributing to severe micro- and macrovascular complications that endanger lives. Individuals with type 2 diabetes commonly exhibit obesity. The elevated prevalence of obesity within the general population has directly correlated with a rise in type 2 diabetes occurrences, thereby rendering effective diabetes management a formidable task. Recent years have witnessed significant advancements in comprehending the physiological aspects of hyperglycemia, consequently leading to the development of numerous innovative medications. During my presentation, I will shed light on the pivotal roles of incretins, dual-cretins, and other emerging therapeutic agents that are reshaping the landscape of diabetes and obesity treatment.
Keywords: Incretin; Type 2 diabetes; Obesity